MGMT and glioma: With the completion of the Human Genome Project, some gene mutations have been shown to be aberrant in patients with gliomas and can be used for diagnosis and treatment of gliomas, such as IDH status, MGMT promoter status, and 1P/19q co-deletion etc [36–38].